Market closedNon-fractional
Insulet/PODD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Insulet
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
Ticker
PODD
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Acton, United States
Employees
3,000
Website
www.insulet.com
Insulet Metrics
BasicAdvanced
$13B
Market cap
57.61
P/E ratio
$3.31
EPS
0.99
Beta
-
Dividend rate
Price and volume
Market cap
$13B
Beta
0.99
Financial strength
Current ratio
3.743
Quick ratio
2.478
Long term debt to equity
177.172
Total debt to equity
182.092
Interest coverage (TTM)
7.66%
Management effectiveness
Return on assets (TTM)
6.74%
Return on equity (TTM)
36.18%
Valuation
Price to earnings (TTM)
57.607
Price to revenue (TTM)
7.487
Price to book
16.9
Price to tangible book (TTM)
20.86
Price to free cash flow (TTM)
97.527
Growth
Revenue change (TTM)
30.17%
Earnings per share change (TTM)
38,259.20%
3-year revenue growth (CAGR)
22.92%
3-year earnings per share growth (CAGR)
196.55%
What the Analysts think about Insulet
Analyst Ratings
Majority rating from 23 analysts.
Insulet Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$442M
-13.36%
Net income
$52M
-50.15%
Profit margin
11.65%
-42.50%
Insulet Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.38
$0.71
$1.40
$0.73
-
Expected
$0.26
$0.40
$0.66
$0.39
$0.56
Surprise
44.52%
76.54%
112.99%
87.90%
-
Insulet News
AllArticlesVideos
Insulet expects to beat revenue estimates on strong insulin pump demand
Reuters·13 hours ago
Insulet's SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
Business Wire·1 month ago
Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Insulet stock?
Insulet (PODD) has a market cap of $13B as of July 27, 2024.
What is the P/E ratio for Insulet stock?
The price to earnings (P/E) ratio for Insulet (PODD) stock is 57.61 as of July 27, 2024.
Does Insulet stock pay dividends?
No, Insulet (PODD) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Insulet dividend payment date?
Insulet (PODD) stock does not pay dividends to its shareholders.
What is the beta indicator for Insulet?
Insulet (PODD) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Insulet stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.